May 13, 2024
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI ® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend and Johnson & Johnson enter into

You are about to leave